Yuval Shaked, PhD

Immunotherapy has become a significant and promising treatment in some cancers, due to its substantial therapeutic activity at advanced-staged cancer. But only 20-40% of patients respond to immunotherapy and in some cases, the treatment causes tumors to metastasize. Dr. Shaked and his team will study the mechanisms involved in the risk of developing brain metastases in immunotherapy-resistant patients. This study should help optimize immunotherapy and reduce its terminal side effects. 

View Grant Recipient Profile